Michael D Wiese

List of Publications by Year
in descending order

137 papers	4,674 citations	117625 34 h-index	110387 64 g-index
138 all docs	138 docs citations	138 times ranked	6479 citing authors

#	Article	IF	Citations
1	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Annals of Oncology, 2015, 26, 13-21.	1.2	439
2	Patient Barriers to and Enablers of Deprescribing: a Systematic Review. Drugs and Aging, 2013, 30, 793-807.	2.7	364
3	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. British Journal of Cancer, 2015, 112, 1888-1894.	6.4	272
4	Review of deprescribing processes and development of an evidenceâ€based, patientâ€centred deprescribing process. British Journal of Clinical Pharmacology, 2014, 78, 738-747.	2.4	246
5	People's Attitudes, Beliefs, and Experiences Regarding Polypharmacy and Willingness to Deprescribe. Journal of the American Geriatrics Society, 2013, 61, 1508-1514.	2.6	182
6	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. British Journal of Cancer, 2017, 117, 913-920.	6.4	145
7	Clinical Outcomes Associated with Medication Regimen Complexity in Older People: A Systematic Review. Journal of the American Geriatrics Society, 2017, 65, 747-753.	2.6	142
8	Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet, The, 2003, 361, 1001-1006.	13.7	129
9	Reply: Comment on â€˜Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancerâ€™. British Journal of Cancer, 2015, 113, 1635-1635.	6.4	127
10	CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel. Circulation: Cardiovascular Genetics, 2014, 7, 895-902.	5.1	107
11	Medication Regimen Complexity and Polypharmacy as Factors Associated With All-Cause Mortality in Older People. Annals of Pharmacotherapy, 2016, 50, 89-95.	1.9	95
12	Alterations in drug disposition in older adults. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 491-508.	3.3	91
13	Development and validation of the patientsâ€™ attitudes towards deprescribing (PATD) questionnaire. International Journal of Clinical Pharmacy, 2013, 35, 51-56.	2.1	85
14	Benefits of deprescribing on patientsâ€™ adherence to medications. International Journal of Clinical Pharmacy, 2014, 36, 26-29.	2.1	77
15	The benefits and harms of deprescribing. Medical Journal of Australia, 2014, 201, 386-389.	1.7	72
16	Feasibility of a Patient-Centered Deprescribing Process to Reduce Inappropriate Use of Proton Pump Inhibitors. Annals of Pharmacotherapy, 2015, 49, 29-38.	1.9	65
17	Medication Regimen Complexity and Number of Medications as Factors Associated With Unplanned Hospitalizations in Older People: A Population-based Cohort Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 831-837.	3.6	63
18	Medication Regimen Complexity and Unplanned Hospital Readmissions in Older People. Annals of Pharmacotherapy, 2014, 48, 1120-1128.	1.9	60

#	Article	IF	Citations
19	Characterisation of major peptides in â€˜jack jumperâ€™ ant venom by mass spectrometry. Toxicon, 2004, 43, 173-183.	1.6	57
20	The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiology and Drug Safety, 2013, 22, 496-502.	1.9	57
21	Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British Journal of Clinical Pharmacology, 2018, 84, 462-476.	2.4	53
22	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 31-49.	3.3	52
23	Original article: Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 437-443.	5.7	46
24	Ultrarush versus semirush initiation of insect venom immunotherapy: AÂrandomized controlled trial. Journal of Allergy and Clinical Immunology, 2012, 130, 162-168.	2.9	44
25	Immediateâ€type hypersensitivity drug reactions. British Journal of Clinical Pharmacology, 2014, 78, 1-13.	2.4	44
26	Predicted metabolic drug clearance with increasing adult age. British Journal of Clinical Pharmacology, 2013, 75, 1019-1028.	2.4	43
27	Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom. Toxicon, 2006, 47, 208-217.	1.6	41
28	Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, R163.	3.5	41
29	Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1025-1035.	3.3	40
30	Quantitation of total and free teriflunomide (A77 1726) in human plasma by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 325-331.	2.8	39
31	Polypharmacy and Medication Regimen Complexity as Factors Associated with Hospital Discharge Destination Among Older People: A Prospective Cohort Study. Drugs and Aging, 2014, 31, 623-630.	2.7	38
32	Extended boiling of peanut progressively reduces IgE allergenicity while retaining T cell reactivity. Clinical and Experimental Allergy, 2016, 46, 1004-1014.	2.9	37
33	Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study. Medical Journal of Australia, 2011, 195, 69-73.	1.7	36
34	Pilosulins: A review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula. Toxicon, 2015, 98, 54-61.	1.6	36
35	Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs, 2020, 29, 475-482.	4.1	36
36	Factors associated with medication regimen complexity in older people: a cross-sectional population-based study. European Journal of Clinical Pharmacology, 2015, 71, 1099-1108.	1.9	34

#	Article	IF	Citations
37	Oral drug challenges in nonâ€steroidal antiâ€inflammatory drugâ€induced urticaria, angioedema and anaphylaxis. Internal Medicine Journal, 2012, 42, 665-671.	0.8	33
38	Costâ€“effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. Pharmacogenomics, 2013, 14, 2013-2021.	1.3	33
39	Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 41-52.	3.3	33
40	Pilosulin 5, a novel histamine-releasing peptide of the Australian ant, Myrmecia pilosula (Jack Jumper) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.0	32
41	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. European Journal of Cancer, 2016, 55, 122-130.	2.8	32
42	Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 213-229.	2.7	30
43	Considerations in selecting postoperative analgesia for pregnant sheep following fetal instrumentation surgery. Animal Frontiers, 2019, 9, 60-67.	1.7	27
44	Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. AAPS Journal, 2017, 19, 1136-1147.	4.4	26
45	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics Journal, 2014, 14, 350-355.	2.0	25
46	Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics, 2012, 13, 1427-1434.	1.3	24
47	Systemic allergy to EDTA in local anesthetic and radiocontrast media. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 225-229.e1.	3.8	24
48	Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Research and Therapy, 2015, 17, 48.	3.5	24
49	The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathiesâ€”a systematic review. European Journal of Clinical Pharmacology, 2015, 71, 411-423.	1.9	23
50	Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. Rheumatology International, 2017, 37, 897-904.	3.0	23
51	Subcutaneous maternal resveratrol treatment increases uterine artery blood flow in the pregnant ewe and increases fetal but not cardiac growth. Journal of Physiology, 2019, 597, 5063-5077.	2.9	23
52	Challenges and Limitations in the Interpretation of Systematic Reviews: Making Sense of Clopidogrel and CYP2C19 Pharmacogenetics. Clinical Pharmacology and Therapeutics, 2013, 94, 376-382.	4.7	22
53	The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. Npj Breast Cancer, 2021, 7, 30.	5.2	22
54	The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrology Dialysis Transplantation, 1999, 14, 2047-2049.	0.7	21

#	Article	IF	Citations
55	Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population. BMC Clinical Pharmacology, 2012, 12, 10.	2.5	21
56	Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2016, 81, 113-123.	2.4	19
57	Myrmecia pilosula (Jack Jumper) ant venom: Validation of a procedure to standardise an allergy vaccine. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 58-65.	2.8	18
58	Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thrombosis and Haemostasis, 2012, 108, 199-200.	3.4	18
59	Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. Journal of Evaluation in Clinical Practice, 2017, 23, 486-493.	1.8	17
60	Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. International Journal of Clinical Practice, 2019, 73, e13375.	1.7	17
61	Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia. Pharmacoeconomics, 2013, 31, 377-391.	3.3	15
62	Leflunomide for Inflammatory Arthritis in End-Stage Renal Disease on Peritoneal Dialysis: A Pharmacokinetic and Pharmacogenetic Study. Annals of Pharmacotherapy, 2013, 47, e15-e15.	1.9	15
63	Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 362-371.	2.5	15
64	Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. Pharmacogenomics, 2016, 17, 1725-1732.	1.3	15
65	The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?. Pharmaceutical Research, 2017, 34, 1544-1550.	3.5	15
66	Intrauterine growth restriction may reduce hepatic drug metabolism in the early neonatal period. Pharmacological Research, 2018, 134, 68-78.	7.1	15
67	Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Scientific Reports, 2020, 10, 18634.	3.3	15
68	Multidose drug dispensing and optimising drug use in older people. Age and Ageing, 2013, 42, 556-558.	1.6	14
69	Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. Therapeutic Advances in Drug Safety, 2015, 6, 186-188.	2.4	14
70	Ten years of publicly funded biological diseaseâ€modifying antirheumatic drugs in Australia. Medical Journal of Australia, 2016, 204, 64-68.	1.7	14
71	A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis. Pharmacological Research, 2021, 173, 105887.	7.1	14
72	Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach. Clinical and Experimental Allergy, 2018, 48, 1222-1234.	2.9	13

#	Article	IF	Citations
73	Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54, 303-310.	2.8	12
74	Disease activity trajectories in early rheumatoid arthritis following intensive <scp>DMARD</scp> therapy over 3 years: association with persistence to therapy. International Journal of Rheumatic Diseases, 2017, 20, 1447-1456.	1.9	12
75	Prevalence and Factors Associated with Analgesic Prescribing in Poly-Medicated Elderly Patients. Drugs and Aging, 2020, 37, 291-300.	2.7	12
76	Targeted pharmacotherapy after somatic cancer mutation screening. F1000Research, 2016, 5, 1551.	1.6	12
77	Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort. Journal of Rheumatology, 2016, 43, 1643-1649.	2.0	11
78	Does poor fetal growth influence the extent of fetal exposure to maternal medications?. Pharmacological Research, 2018, 130, 74-84.	7.1	10
79	Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine. Clinical Breast Cancer, 2020, 20, e220-e228.	2.4	10
80	The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data. Frontiers in Oncology, 2020, 10, 1130.	2.8	10
81	Fetal cardiovascular response to acute hypoxia during maternal anesthesia. Physiological Reports, 2020, 8, e14365.	1.7	10
82	A literature review of treatment-specific clinical prediction models in patients with breast cancer. Critical Reviews in Oncology/Hematology, 2020, 148, 102908.	4.4	10
83	LC-MS/MS analysis of vitamin D3 metabolites in human serum using a salting-out based liquid-liquid extraction and DAPTAD derivatization. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1173, 122654.	2.3	10
84	Using Time-Resolved Fluorescence to Measure Serum Venom-Specific IgE and IgG. PLoS ONE, 2011, 6, e16741.	2.5	9
85	PTPN22R620W minor allele is a genetic risk factor for giant cell arteritis. RMD Open, 2016, 2, e000246.	3.8	9
86	Intracellular CD3⁺T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration. Drug Metabolism and Disposition, 2017, 45, 8-16.	3.3	9
87	Nuances to precision dosing strategies of targeted cancer medicines. Pharmacology Research and Perspectives, 2020, 8, e00625.	2.4	9
88	Methamphetamine administration increases hepatic CYP1A2 but not CYP3AÂactivity in female guinea pigs. PLoS ONE, 2020, 15, e0233010.	2.5	9
89	Redox ratio in the left ventricle of the growth restricted fetus is positively correlated with cardiac output. Journal of Biophotonics, 2021, 14, e202100157.	2.3	9
90	Raised INR with Concurrent Warfarin and Azithromycin. Journal of Pharmacy Practice and Research, 1999, 29, 159-161.	0.2	8

#	Article	IF	Citations
91	Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Therapeutic Advances in Drug Safety, 2014, 5, 62-66.	2.4	8
92	Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 983-989.	3.4	8
93	The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinsonâ€™s disease in C57BL/6 mice. NeuroToxicology, 2021, 85, 254-264.	3.0	8
94	Efficacy of ant venom immunotherapy and whole body extracts. Journal of Allergy and Clinical Immunology, 2005, 116, 464-465.	2.9	7
95	The rheumatoid arthritis susceptibility polymorphismPTPN22C1858T is not associated with leflunomide response or toxicity. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 555-560.	1.5	7
96	Determining the acceptable level of physician compliance with a treatâ€toâ€target strategy in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 2017, 20, 576-583.	1.9	7
97	Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 1-8.	2.8	7
98	Opioid prescribing and risk of drug-opioid interactions in older discharged patients with polypharmacy in Australia. International Journal of Clinical Pharmacy, 2021, 43, 365-374.	2.1	7
99	Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management. Clinical Reviews in Allergy and Immunology, 2022, 62, 123-144.	6.5	7
100	Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling. Journal of Pharmaceutical and Biomedical Analysis, 2021, 203, 114171.	2.8	7
101	Individualization of leflunomide dosing in rheumatoid arthritis patients. Personalized Medicine, 2014, 11, 449-461.	1.5	6
102	Costâ€“effectiveness of genotyping to guide treatment. Pharmacogenomics, 2014, 15, 727-729.	1.3	6
103	Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in inÂvitro and inÂvivo diagnoses of allergen sensitization and in allergen immunotherapy. Clinical and Experimental Allergy, 2017, 47, 1478-1490.	2.9	6
104	Impact of resveratrolâ€mediated increase in uterine artery blood flow on fetal haemodynamics, blood pressure and oxygenation in sheep. Experimental Physiology, 2021, 106, 1166-1180.	2.0	6
105	Intrauterine growth restriction alters the activity of drug metabolising enzymes in the maternal-placental-fetal unit. Life Sciences, 2021, 285, 120016.	4.3	6
106	Targeted pharmacotherapy after somatic cancer mutation screening. F1000Research, 2016, 5, 1551.	1.6	6
107	Quantitation of methotrexate polyglutamates in human whole blood, erythrocytes and leukocytes collected via venepuncture and volumetric absorptive micro-sampling: a green LCâ€“MS/MS-based method. Analytical and Bioanalytical Chemistry, 2022, 414, 6029-6046.	3.7	6
108	Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 205-210.	0.7	5

#	Article	IF	Citations
109	Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes. Journal of Pharmacological and Toxicological Methods, 2020, 106, 106934.	0.7	5
110	Therapeutic Potential of a Novel Vitamin D3 Oxime Analogue, VD1-6, with CYP24A1 Enzyme Inhibitory Activity and Negligible Vitamin D Receptor Binding. Biomolecules, 2022, 12, 960.	4.0	5
111	Reframe the pain: Divided attention and positive memory reframing to reduce needle pain and distress in childrenâ€"A feasibility randomized controlled trial. European Journal of Pain, 2022, 26, 1702-1722.	2.8	5
112	Difficulties Reducing Inappropriate Prescribing of Proton Pump Inhibitors in the Elderly. Drugs and Aging, 2012, 29, 925-926.	2.7	4
113	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. British Journal of Clinical Pharmacology, 2015, 79, 777-788.	2.4	4
114	Improving community access to terminal phase medicines in Australia: identification of the key considerations for the implementation of a â€˜core medicines listâ€™. Australian Journal of Primary Health, 2017, 23, 373.	0.9	4
115	COVID-19: can we treat the mother without harming her baby?. Journal of Developmental Origins of Health and Disease, 2021, , 1-11.	1.4	4
116	Impact of maternal late gestation undernutrition on surfactant maturation, pulmonary blood flow and oxygen delivery measured by magnetic resonance imaging in the sheep fetus. Journal of Physiology, 2021, 599, 4705-4724.	2.9	4
117	Hepatic cytochrome P450 function is reduced by life-long Western diet consumption in guinea pig independent of birth weight. Life Sciences, 2021, 287, 120133.	4.3	4
118	Perceived and actual paracetamol dosing inÂoverweight and obese children. European Journal of Hospital Pharmacy, 2012, 19, 438-442.	1.1	3
119	Metabolic and safety issues for multiple sclerosis pharmacotherapy â€“ opportunities for personalised medicine. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1145-1159.	3.3	3
120	The PTPN22 gene is associated with idiopathic inflammatory myopathy. Muscle and Nerve, 2017, 55, 270-273.	2.2	3
121	Repeat serological testing for antiâ€citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. Internal Medicine Journal, 2020, 50, 818-822.	0.8	3
122	The impact of intrauterine growth restriction on cytochrome P450 enzyme expression and activity. Placenta, 2020, 99, 50-62.	1.5	3
123	Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110090.	2.7	3
124	Maternal-placental-fetal drug metabolism is altered by late gestation undernutrition in the pregnant ewe. Life Sciences, 2022, 298, 120521.	4.3	3
125	Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology, 2023, 62, 583-595.	1.9	3
126	Unexpected Orthostatic Hypotension with Venlafaxine. Journal of Pharmacy Practice and Research, 1999, 29, 215-216.	0.2	2

#	Article	IF	Citations
127	Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?. International Journal of Clinical Practice, 2016, 70, 340-350.	1.7	2
128	Putting recommendations into practice: Australian rheumatologistsâ€™ opinions on leflunomide use in rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 791-798.	2.2	2
129	Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. European Journal of Clinical Pharmacology, 2021, 77, 1357-1368.	1.9	2
130	Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. Bladder Cancer, 2022, 8, 81-88.	0.4	2
131	A modelâ€based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. British Journal of Clinical Pharmacology, 2016, 81, 1046-1057.	2.4	1
132	Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological diseaseâ€modifying antirheumatic drugs have influenced the use of leflunomide. International Journal of Rheumatic Diseases, 2017, 20, 1795-1797.	1.9	1
133	Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. Translational Cancer Research, 2016, 5, S31-S34.	1.0	1
134	Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 387-402.	1.6	1
135	Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomideâ€"Should Consideration Be Given to Cannalicular Efflux Transporters?. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 564-564.	2.5	0
136	Efficacy and safety of statins in ethnic differences: aÂlesson for application in Indigenous Australian patient care. Pharmacogenomics, 2021, 22, 553-571.	1.3	0
137	BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.. Journal of Clinical Oncology, 2015, 33, e14605-e14605.	1.6	0